At a glance
ClinicalIndex Comparison RecordN/ACompleted· 31 enrolled
Drug / intervention
Boston Scientific Vercise PC IPG with directional DBS leaddevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Noninvasive Biomarkers to Advance Emerging DBS Electrode Technologies in Parkinson's Disease (SUNDIAL, SUbthalamic Nucleus DIrectionAL vs Circular Stimulation Study)
In Brief
A clinical study evaluating Boston Scientific Vercise PC IPG with directional DBS lead for Parkinson Disease. Completed, enrolled 31 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the clinical efficacy of directional DBS electrode technology and whether electrophysiology biomarkers can predict effective contact segments for chronic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedNov 2017
Primary CompletionAug 2022
Study CompletionJul 2024
TodayJul 2026
First PostedNov 27, 2017
Enrollment StartNov 3, 2017
Primary CompletionAug 15, 2022
Study CompletionJul 31, 2024
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 8.6 years ago
Interventions
Boston Scientific Vercise PC IPG with directional DBS leaddevice
Deep brain stimulation